181 related articles for article (PubMed ID: 2578092)
1. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Jayaram HN; Ardalan B; Deas M; Johnson RK
Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
[TBL] [Abstract][Full Text] [Related]
2. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Rosenfeld H; Roberts J
Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
[TBL] [Abstract][Full Text] [Related]
4. Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia.
Ardalan B; Chandrasekaran B; Hrishikeshavan HJ
Cancer Chemother Pharmacol; 1985; 15(1):44-8. PubMed ID: 2408773
[TBL] [Abstract][Full Text] [Related]
5. Acivicin. An antitumor antibiotic.
Poster DS; Bruno S; Penta J; Neil GL; McGovren JP
Cancer Clin Trials; 1981; 4(3):327-30. PubMed ID: 7026076
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501).
Meck RA; Clubb KJ; Allen LM; Yunis AA
Cancer Res; 1981 Nov; 41(11 Pt 1):4547-53. PubMed ID: 7306976
[TBL] [Abstract][Full Text] [Related]
7. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
Holcenberg JS
Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
[TBL] [Abstract][Full Text] [Related]
8. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.
Jayaram HN; Cooney DA; Ryan JA; Neil G; Dion RL; Bono VH
Cancer Chemother Rep; 1975; 59(3):481-91. PubMed ID: 1147
[TBL] [Abstract][Full Text] [Related]
9. Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenocarcinomas in vivo.
Ardalan B; Arakawa M; Villacorte D; Jayaram H; Cooney DA
Biochem Pharmacol; 1982 Apr; 31(8):1509-13. PubMed ID: 6178415
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.
Fischer PH; Pamukcu R; Bittner G; Willson JK
Cancer Res; 1984 Aug; 44(8):3355-9. PubMed ID: 6744269
[TBL] [Abstract][Full Text] [Related]
11. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
12. In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma.
Aoki T; Sebolt J; Weber G
Biochem Pharmacol; 1982 Mar; 31(6):927-32. PubMed ID: 7082374
[TBL] [Abstract][Full Text] [Related]
13. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin.
Nichols KE; Chitneni SR; Moore JO; Weinberg JB
Blood; 1989 Oct; 74(5):1728-37. PubMed ID: 2790198
[TBL] [Abstract][Full Text] [Related]
14. Inactivation by acivicin of carbamoyl-phosphate synthetase II of human colon carcinoma.
Sebolt JS; Aoki T; Eble JN; Glover JL; Weber G
Biochem Pharmacol; 1985 Jan; 34(1):97-100. PubMed ID: 3966920
[TBL] [Abstract][Full Text] [Related]
15. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
16. Radiometric enzyme-inhibition technique for measuring acivicin in plasma.
Jayaram HN; Kensler TW; Ardalan B
Cancer Treat Rep; 1981; 65(5-6):491-4. PubMed ID: 7237469
[TBL] [Abstract][Full Text] [Related]
17. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
Williams MG; Earhart RH; Bailey H; McGovren JP
Cancer Res; 1990 Sep; 50(17):5475-80. PubMed ID: 2386952
[TBL] [Abstract][Full Text] [Related]
18. Multi-enzyme-targeted chemotherapy by acivicin and actinomycin.
Weber G; Prajda N; Lui MS; Denton JE; Aoki T; Sebolt J; Zhen YS; Burt ME; Faderan MA; Reardon MA
Adv Enzyme Regul; 1982; 20():75-96. PubMed ID: 6180609
[TBL] [Abstract][Full Text] [Related]
19. Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; Bhuyan BK; Blowers CL; Kuentzel SL
Adv Enzyme Regul; 1978; 17():375-98. PubMed ID: 757314
[No Abstract] [Full Text] [Related]
20. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
Kessel D; Wilberding C
Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
